Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Oruka Therapeutics Inc (ORKA)

180 + Investors. Track Smart Money conviction in ORKA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +41
Streak
7Q ▲
Buyers last Q
70%

Smart Money Signals — ORKA

Based on 182 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 7 quarters in a row

last 6Q
For 7 consecutive quarters, more hedge funds added ORKA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
182 hedge funds hold ORKA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +164% more funds vs a year ago

fund count last 6Q
+113 new funds entered over the past year (+164% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 70% buying

126 buying53 selling
Last quarter: 126 funds were net buyers (63 opened a brand new position + 63 added to an existing one). Only 53 were sellers (31 trimmed + 22 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+18 vs last Q)

new funds entering per quarter
Funds opening a new ORKA position: 26 → 32 → 45 → 63. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 62% entered in last year

■ 3% conviction (2yr+) ■ 35% medium ■ 62% new
Only 6 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Price up while funds trimmed (+61% value, -1% shares)

Value
+61%
Shares
0%
Last quarter: total value of institutional ORKA holdings rose +61% even though funds reduced share count by 1%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
🚀

Acceleration phase — new buyers rushing in

16 → 26 → 32 → 45 → 63 new funds/Q
New funds entering each quarter: 26 → 32 → 45 → 63. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🌱

Early stage — 70% of holders entered in last year

■ 5% veterans ■ 25% 1-2yr ■ 70% new
Of 185 current holders: 130 (70%) entered in the past year, only 9 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds
42 of 182 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
6.4
out of 10
Moderate Exit Risk
Exit risk score 6.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ORKA

In 2026 Q1, 126 hedge funds were net buyers of ORKA (63 opened a new position, 63 added to an existing one), while 53 reduced or exited (31 trimmed, 22 sold completely) — a 70% buyer ratio, indicating clear institutional accumulation. This marks 7 consecutive quarters of net institutional buying — a persistent conviction signal. 29% of total institutional value in ORKA is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +41 funds (more new holders than closures). Total institutional holders: 182.

Hedge Fund Ownership: ORKA

How many hedge funds hold ORKA — quarterly history vs. share price
Quarterly hedge fund ownership of ORKA vs. share price

Market Analysis: ORKA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ORKA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Oruka Therapeutics Inc (ORKA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ORKA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
ORKA
+42.5%
XLV
+4.9%

ORKA outperformed XLV by +37.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
ORKA
+12.9%
XLV
+6.0%

Since the filing became public, ORKA outperformed XLV by +6.9% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

21 top-rated funds 10 high-conviction
Consensus
5.8
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: ORKA
180 + Investors

Track Smart Money conviction in ORKA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 180 141 27.66%
13F Shares 52M 53M -0.89%
Total Value $2.55B $1.58B 60.97%
New Positions 62 45 +17
Increased Positions 62 54 +8
Closed Positions 23 9 +14
Reduced Positions 30 17 +13
Total Calls 2 1 100.0%
Total Puts 2 1 100.0%
PUT/CALL Ratio 1.0 1.0 Neutral

Statistics: ORKA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

180 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ORKA. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ORKA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Remedium Capital Partners, LLC 28.98% 1,889,115 $92.7M
2 Fairmount Funds Management LLC 13.13% 3,705,262 $181.7M
3 Avidity Partners Management LP 11.77% 760,424 $52.0M
4 Venrock Adviser, LLC 7.60% 4,148,428 $203.5M
5 Kalehua Capital Management LLC 4.90% 118,524 $5.8M
6 Cable Car Capital, LP 3.39% 200,000 $9.8M
7 B Group, Inc. 2.73% 75,000 $3.7M
8 Synergy Asset Management, LLC 2.48% 476,196 $23.4M
9 Paradigm Biocapital Advisors LP 2.33% 2,320,316 $113.8M
10 Sr One Capital Management, LP 2.31% 430,330 $21.1M
11 Superstring Capital Management LP 2.23% 63,591 $3.1M
12 Great Point Partners LLC 2.07% 183,330 $9.0M
13 Deep Track Capital, LP 1.63% 2,034,203 $99.8M
14 Jones Hill Capital LP 1.48% 140,843 $6.9M
15 Atika Capital Management LLC 1.42% 229,900 $11.3M
16 Perceptive Advisors LLC 1.34% 1,395,501 $68.4M
17 Cormorant Asset Management, LP 1.31% 533,340 $26.2M
18 Affinity Asset Advisors, LLC 1.27% 499,673 $24.5M
19 Moody Aldrich Partners LLC 1.19% 135,061 $6.6M
20 HighVista Strategies LLC 1.07% 78,911 $3.9M
21 Rtw Investments, LP 1.00% 2,058,148 $101.0M
22 Ikarian Capital, LLC 0.96% 242,021 $11.9M
23 Sio Capital Management, LLC 0.93% 132,496 $6.5M
24 PFM Health Sciences, LP 0.78% 174,052 $8.5M
25 Silverarc Capital Management, LLC 0.76% 150,908 $7.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Oruka Therapeutics Inc (ORKA)

What does the Smart Money Trend signal show for ORKA?

Buying streak — 7 quarters in a row: For 7 consecutive quarters, more hedge funds added ORKA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ORKA?

More buyers than sellers — 70% buying: Last quarter: 126 funds were net buyers (63 opened a brand new position + 63 added to an existing one). Only 53 were sellers (31 trimmed + 22 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ORKA holders?

Strong quality — 29% AUM from major funds: 42 of 182 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ORKA?

Mostly new holders — 62% entered in last year: Only 6 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Oruka Therapeutics Inc (ORKA) following the 2026 Q1 hedge fund 13F filings?

As of today, ORKA has moved +12.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of +6.9%. Since the quarter end (March 31, 2026), ORKA has gained +42.5% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →